About ARK Genomic Revolution ETF
The ARK Genomic Revolution ETF (ARKG) is an actively managed exchange-traded fund that seeks long-term growth of capital through investing in companies that are relevant to the fund’s theme of genomics revolution. Companies within the ETF are focused on enhancing the quality of human life by incorporating genomic and scientific advancements into their business, working in the fields of targeted therapeutics, the gene-editing technology known as CRISPR, bioinformatics, stem cell technology, molecular diagnostics, and agricultural biology. The fund, founded in 2014, has an expense ratio of 0.75% and net assets worth $8.5bn. Top-weighted holdings of ARKG include Pacific Biosciences of California, Vertex Pharmaceuticals, Teladoc Health, Accolade, Fate Therapeutics, and Twist Bioscience. Start spread betting or trading CFDs on our ARK Genomic Revolution ETF price.
Constituent weightings
Component
Weighting
1 Day
1 Month
3 Month
Trading hours shown in London local time